Study of Dj-1 protein in tissue specimens, cultured cells and serum of prostate cancer patients

Lisitskaya, K. V.; Eremina, L. S.; Ivanov, Alexei V.; Kovalyova, M. A.; Охриц, В. Е.; Toropygin, I. Yu.; Kovalyov, L. I.; Shishkin, S. S.

doi:10.18097/pbmc20115704392

Cited by 6 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results in tissue samples demonstrated that Dj-1 exists in two isoforms which both of which were at significantly higher abundance in PCa than in BPH tissues. The results were also confirmed in the cell lines, whereas there was no dramatic difference between cases and controls in the protein abundance in serum [57]. difference was observed between tumors with and without BCR.…”

Section: Results: 10 Years Of Tissue Proteomics In Prostate Cancersupporting

confidence: 57%

Tissue proteomics studies in the investigation of prostate cancer

Mantsiou

Vlahou

Zoidakis

2018

Expert Review of Proteomics

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the leading causes of death in the male population worldwide. Various clinical samples such as urine, blood serum, and prostatic fluid have been commonly used for the identification of PCa-associated molecular changes. Tissue, the site of oncogenesis, is increasingly gaining more attention as a study material for studies aimed at the discovery of biomarkers for predicting the disease outcome and therapeutic targets. Areas covered: This review is the output of a systematic literature search on PubMed to retrieve articles relevant to the proteomic analysis of tissues for the study of PCa. Studies performed during the last 10 years using human tissues are summarized. Expert commentary: Multiple proteomics studies were performed in the past 10 years focusing on PCa initial diagnosis and staging. Even though some reproducible findings have been reported, many studies lacked adequate validation of findings and relied on relatively lower-resolution proteomics techniques compared to the current state of the art. Incorporation of high-resolution proteomics techniques, including investigations of protein post-translational modifications (PTMs), is expected in the near future to complement other -omics and enhance current efforts toward the molecular subtyping of PCa for patient stratification.

show abstract

Section: Results: 10 Years Of Tissue Proteomics In Prostate Cancersupporting

confidence: 57%

Tissue proteomics studies in the investigation of prostate cancer

Mantsiou

Vlahou

Zoidakis

2018

Expert Review of Proteomics

View full text Add to dashboard Cite

show abstract

“…[25] In addition, these results are close to the other previous studies. [22,23] In addition, we found a significant association with cyclin D1/DJ-1 overexpression with tumor size, stage, and GS > 7. Moreover, similar results validated the same association and were reported by many studies.…”

Section: Discussionmentioning

confidence: 53%

“…[21] As regards DJ-1 immunostaining, our presenting results showed that 85% of PC was positive, compared to 2.5% was positive in BPH group; these findings are inconsistent with other earlier studies. [22,23] The metaanalysis involved fourteen studies including 1,947 cancer patients and revealed that DJ-1 was an important biomarker in tumor evaluation and outcome. [24] The findings of our study provided that involvement in cyclin D1 and DJ-1, and in all the studied stages of PC compared to BPH.…”

Section: Discussionmentioning

confidence: 99%

Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

Mohammed

Ibrahim

Atwa

et al. 2019

Forum of Clinical Oncology

View full text Add to dashboard Cite

BackgroundDisturbance in cell cycle regulatory genes is a common finding among many types of cancers. The aim of this study is to evaluate the role of cyclin D1 and DJ-1 in benign prostatic hyperplasia (BPH) and prostate cancer (PC).MethodThe current study enclosed 40 patients diagnosed with PC and 40 cases of BPH. The expression level of cyclin D1 and DJ-1 were evaluated by immunohistochemistry (IHC). Cyclin D1 scored depending on the percentage of stained nuclear tumor cells. While scoring of DJ-1 was based on intensity. The results were correlated with clinicopathological features and outcome.ResultsIn the PC group, cyclin D1 was detected in 95% and overexpressed in 42.5%, DJ-1 was positively stained in 85% and overexpressed in 47.5%. Meanwhile, in the BPH group, cyclin D1 was not detected and DJ-1 stained in only 2.5%. There was a statistically significant difference in Gleason score (GS), tumor stage, size, and treatment failure (p =< 0.001). In the terms of PC diagnosis prediction, although cyclin D1 was more specific (100%), DJ-1 is more sensitive than cyclin D1 (80%, 70%, respectively) (p = 0.000).ConclusionsCyclin D1 and DJ-1 may emerge as a promising way for diagnosis of PC in certain circumstances, as the presence of insufficient tissue sampling, small foci of carcinoma or benign lesions mimic PC. This is in addition to the known role of cyclin D1 and DJ-1 in PC prognosis.

show abstract

“…For instance, marked variation is seen in serum DJ-1 levels in patients with benign prostatic hypertrophy in comparison to serum DJ-1 levels in patients with prostate carcinomas, with higher levels being seen in the latter [2]. As a result, serum DJ-1 appears to be a biomarker with considerable promise for identifying prostate malignancies.…”

mentioning

confidence: 99%

DJ-1 and its emerging role as a biomarker of systemic malignancies besides lung carcinomas

Kapoor

2012

Mol Biol Rep

View full text Add to dashboard Cite

Study of Dj-1 protein in tissue specimens, cultured cells and serum of prostate cancer patients

Cited by 6 publications

References 14 publications

Tissue proteomics studies in the investigation of prostate cancer

Tissue proteomics studies in the investigation of prostate cancer

Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

DJ-1 and its emerging role as a biomarker of systemic malignancies besides lung carcinomas

Contact Info

Product

Resources

About